title: Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets.
abstract: We have studied the influence of a wide concentration range of islet amyloid polypeptide (IAPP) on both glucagon and insulin release stimulated by various types of secretagogues. In an islet incubation medium devoid of glucose, the rate of glucagon release being high, we observed a marked suppressive action by low concentrations of IAPP, 10(-10) and 10(-8) M, on glucagon release. Similarly, glucagon release stimulated by L-arginine, the cholinergic agonist carbachol, or the phosphodiesterase inhibitor isobutylmethyl xanthine (IBMX), an activator of the cyclic AMP system, was inhibited by IAPP in the 10(-10) and 10(-8) M concentration range. Moreover, basal glucagon release at 7 and 10 mM glucose was suppressed by IAPP. In contrast, IAPP exerted a dual action on insulin release. Hence, low concentrations of IAPP brought about a modest increase of basal insulin secretion at 7 mM glucose and also of insulin release stimulated by carbachol. High concentrations of IAPP, however, inhibited insulin release stimulated by glucose (10 and 16.7 mM), IBMX, carbachol and L-arginine. In conclusion, our data suggest that IAPP has complex effects on islet hormone secretion serving as an inhibitor of glucagon release and having a dual action on insulin secretion exerting mainly a negative feedback on stimulated and a positive feedback on basal insulin release.
authors.affiliation: Department of Pharmacology, Institute of Physiological Sciences, University of Lund, BMC F13S-221 84 Lund, Sweden.
authors.forename: Björn
authors.initials: B
authors.lastname: Akesson
authors.forename: Georgios
authors.initials: G
authors.lastname: Panagiotidis
authors.forename: Per
authors.initials: P
authors.lastname: Westermark
authors.forename: Ingmar
authors.initials: I
authors.lastname: Lundquist
mesh_terms: D015056:1-Methyl-3-isobutylxanthine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000682:Amyloid / Q000494:pharmacology*; D000818:Animals; D001120:Arginine / Q000737:chemistry / Q000494:pharmacology; D002217:Carbachol / Q000037:antagonists & inhibitors / Q000494:pharmacology; D018679:Cholinergic Agonists / Q000378:metabolism / Q000494:pharmacology; D003470:Culture Media; D005260:Female; D005934:Glucagon / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D005947:Glucose / Q000172:deficiency / Q000378:metabolism / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D058228:Islet Amyloid Polypeptide; D007515:Islets of Langerhans / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D010726:Phosphodiesterase Inhibitors / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000682:Amyloid; D018679:Cholinergic Agonists; D003470:Culture Media; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D010726:Phosphodiesterase Inhibitors; D002217:Carbachol; D005934:Glucagon; D001120:Arginine; D005947:Glucose; D015056:1-Methyl-3-isobutylxanthine